Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 2
1990 2
1993 1
1994 2
1996 1
1997 1
1998 2
2001 3
2003 4
2004 3
2005 7
2006 3
2007 1
2008 1
2009 3
2010 3
2011 2
2012 5
2013 2
2014 1
2015 1
2017 2
2018 7
2019 5
2020 2
2021 3
2022 1
2023 1
2024 6
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study.
Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad A, Diaz-de-Heredia C. Locatelli F, et al. Among authors: st pierre a. Blood. 2024 Nov 14;144(20):2095-2106. doi: 10.1182/blood.2023022565. Blood. 2024. PMID: 39046767 Free article. Clinical Trial.
Pathology in Practice.
Stilwell JM, St Pierre A, Epstein KL, Gottdenker NL. Stilwell JM, et al. Among authors: st pierre a. J Am Vet Med Assoc. 2020 Sep 15;257(6):603-606. doi: 10.2460/javma.257.6.603. J Am Vet Med Assoc. 2020. PMID: 32857007 Free article. No abstract available.
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, Güngör T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C. Locatelli F, et al. Among authors: st pierre a. Lancet Haematol. 2024 Aug;11(8):e580-e592. doi: 10.1016/S2352-3026(24)00174-1. Epub 2024 Jul 10. Lancet Haematol. 2024. PMID: 39002551 Clinical Trial.
Enhancing Reviews and Surveillance to Eliminate Maternal Mortality.
Callahan T, Zaharatos J, St Pierre A, Merkt PT, Goodman D. Callahan T, et al. Among authors: st pierre a. J Womens Health (Larchmt). 2021 Aug;30(8):1068-1073. doi: 10.1089/jwh.2021.0357. J Womens Health (Larchmt). 2021. PMID: 34410869 Free PMC article.
Identifying Deaths During and After Pregnancy: New Approaches to a Perennial Challenge.
Trost SL, Beauregard J, Petersen EE, Cox S, Chandra G, St Pierre A, Rodriguez M, Goodman D. Trost SL, et al. Among authors: st pierre a. Public Health Rep. 2023 Jul-Aug;138(4):567-572. doi: 10.1177/00333549221110487. Epub 2022 Jul 23. Public Health Rep. 2023. PMID: 35872654 Free PMC article. No abstract available.
71 results